Curriculum Vitae
HIROYUKI KOIDE, Ph.D.
ADDRESS:52-1 Yada, Suruga-ku Shizuoka 422-8526, Japan
TEL: +81 54 264 5702
FAX: +81 54 264 5705
E-mail: hkoide@u-shizuoka-ken.ac.jp
PRESENT STATUS:
Assistant Professor
Department of Medical Biochemistry
School of Pharmaceutical Sciences
University of Shizuoka
EDUCATION
Bachelor of Science in Biochemistry, 2002-2006
Josai University, Saitama-ken, Japan
Title: Synthesis of N-guanidino-1,7-diaminoheptane (GC7) analogs
Thesis advisor: Prof. Akia Shirahata
Master of Sciences in Biochemistry, 2006-2008
University of Shizuoka, Shizuoka-ken, JapanTitle: Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated
nanocarriers
Thesis advisor: Prof. Naoto Oku
Ph. D. in Pharmaceutical Sciences, 2008-2011
University of Shizuoka, Shizuoka-ken, Japan
Title: Cancer RNA interference therapy targeting to mammalian target of rapamycin
Thesis advisor: Prof. Naoto Oku
Post doc in Chemistry, 2011-2013
University of California, Irvine
Title: Design of a novel plastic antibody to capture and inhibition of angiogenesis-related growth factors forcancer therapy
Advisor: Prof. Kenneth J. SheaQUALIFICATION:Pharmacist (Japanese): registered in JAPAN 6/2006

PUBLICATION(a) ARTICLES
1) Koide H*, Okishima A, Hoshino Y, Kamon Y, Yoshimatsu K, Saito K, Yamauchi I, Ariizumi S, Zhou Y, Xiao T,Goda K, Oku N, Asai T, Shea K.J., Synthetic hydrogel nanoparticles for sepsis therapy., NatureCommunications, 12, 5552, 2021. *Corresponding Author
2) Yasuno G, Koide H*, Oku N, Asai T., Influence of Purification Process on the Function of Synthetic Polymer
Nanoparticles. Chem Pharm Bull. 69, 773-780, 2021.
3) Koide H*, Yamauchi I, Hoshino Y, Yasuno G, Okamoto T, Akashi S, Saito K, Oku N, Asai T., Design of abioticpolymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood.,
Biomater Sci. 9, 5588-5598, 2021.

4) Koide H*, Hayashi N, Yasuno G, Okishima A, Hoshino Y, Egami H, Hamashima Y, Oku N, Asai T., Design ofsynthetic polymer nanoparticles that inhibit glucose absorption from the intestine. Biochem Biophys ResCommun. 561, 1-6, 2021.
5) Koide H*, Suzuki H, Ochiai H, Egami H, Hamashima Y, Oku N, Asai T., Enhancement of target toxin
neutralization effect in vivo by PEGylation of multifunctionalized lipid nanoparticles. Biochem Biophys ResCommun. 555, 32-39, 2021.
6) Koide H*, Hirano S, Ide T, Saito K, Suzuki H, Yasuno G, Hamashima Y, Yonezawa Y, Oku N, Asai T.,
Engineering of Lipid Nanoparticles by the Multifunctionalization of the Surface with Amino Acid Derivatives
for the Neutralization of a Target Toxic Peptide. Adv Funct Mater., 2005641, 2020.
7) Hirai Y, Saeki R, Song F, Koide H, Fukata N, Tomita K, Maeda N, Oku N, Asai T., Charge-reversible lipid
derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery. Int J Pharm. 585,119479, 2020.
8) Kikuchi T, Fukuta T, Agato Y, Yanagida Y, Ishii T, Koide H, Shimizu K, Oku N, Asai T., Suppression of cerebral
ischemia/reperfusion injury by efficient release of encapsulated ifenprodil from liposomes under weakly
acidic pH conditions. J Pharm Sci. 108, 3823-3830, 2019.
9) Koide H, Fukuta T, Okishima A, Ariizumi S, Kiyokawa C, Tsuchida H, Nakamoto M, Yoshimatsu K, Ando H,Dewa T, Asai T, Oku N, Hoshino Y, Shea KJ., Engineering the Binding Kinetics of Synthetic Polymer
Nanoparticles for siRNA Delivery. Biomacromolecules. 20, 3648-3657, 2019.
10) Zang L, Shimada Y, Nakayama H, Chen W, Okamoto A, Koide H, Oku N, Dewa T, Shiota M, Nishimura N.,
Therapeutic Silencing of Centromere Protein X Ameliorates Hyperglycemia in Zebrafish and Mouse Modelsof Type 2 Diabetes Mellitus. Front Genet. 10, 693, 2019.
11) Sako M, Song F, Okamoto A, Koide H, Dewa T, Oku N, Asai T., Key determinants of siRNA delivery mediatedby unique pH-responsive lipid-based liposomes. Int J Pharm. 569, 118606, 201912) Song F, Sakurai N, Okamoto A, Koide H, Oku N, Dewa T, Asai T., Design of a Novel PEGylated Liposomal
Vector for Systemic Delivery of siRNA to Solid Tumors. Biol Pharm Bull. 42, 996-1003, 2019.
13) Okishima A, Koide H*, Hoshino Y, Egami H, Hamashima Y, Oku N, Asai T., Design of Synthetic Polymer
Nanoparticles Specifically Capturing Indole, a Small Toxic Molecule. Biomacromolecules. 4, 1644-1654,
2019. *Correspond Author14) Okamoto A, Koide H, Morita N, Hirai Y, Kawato Y, Egami H, Hamashima Y, Asai T, Dewa T, Oku N., Rigorous
control of vesicle-forming lipid pKa by fluorine-conjugated bioisosteres for gene-silencing with siRNA. J.
Control Release. 295, 87-92. 2019.
15) Koide H, Yoshimatsu K, Hoshino Y, Ariizumi S, Okishima A, Ide T, Egami H, Hamashima Y, Nishimura Y,Kanazawa H, Miura Y, Asai T, Oku N, Shea KJ., Sequestering and inhibiting a vascular endothelial growth
factor in vivo by systemic administration of a synthetic polymer nanoparticle., J. Control Release. 295,
13-20. 2019.
16) Okamoto A, Asai T, Hirai Y, Shimizu K, Koide H, Minamino T, Oku N., Systemic Administration of siRNA with
Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.,
Mol Pharm., 4, 1495-1504, 2018.

17) Koide H, Tsuchida H, Nakamoto M, Okishima A, Ariizumi S, Kiyokawa C, Asai T, Hoshino Y, Oku N, Rational
designing of an antidote nanoparticle decorated with abiotic polymer ligands for capturing and neutralizing
target toxins, J Control Release, 268, 335-342, 2017.
18) Koide H, Yoshimatsu K, Hoshino Yu, Lee S, Okajima A, Ariizumi S, Narita Y, Yonamine Y, Weisman A C,
Nishimura Y, Oku N, Miura Y, and Shea KJ, A Polymer Nanoparticle with Engineered Affinity for a VascularEndothelial Growth Factor (VEGF165), Nature Chemistry, 9, 715–722, 2017.
19) Fukuta T, Asai T, Yanagida Y, Namba M, Koide H, Shimizu K and Oku N, Combination therapy with liposomal
neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke, FASEB J., 5,1879-1890, 2017.
20) Fukuta T, Asai T, Ishii T, Koide H, Kiyokawa C, Hashimoto M, Kikuchi T, Shimizu K, Harada N, Tsukada H,Oku N, Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of
mitochondrial complex-I activity, Sci Rep., 6, 30127, 2016.
21) Fukuta T, Asai T, Sato A, Namba M, Yanagida Y, Kikuchi T, Koide H, Shimizu K, Oku N, Neuroprotection
against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. Int J Pharm.,506, 129-137. 2016.
22) Koide H, Okamoto A, Tsuchida H, Ando H, Ariizumi S, Kiyokawa C,Hashimoto M, Asai T, Dewa T, Oku N,
One-step encapsulation of siRNA between lipid-layers of multi-layer polycation liposomes by lipoplex
freeze-thawing, J Control Release, 228, 1-8, 2016.
23) Waki N, Kuwabara Y, Yoshikawa Y, Suganuma H, Koide H, Oku N, Ohashi N, Amelioration of Citrobacterrodentium proliferation in early stage of infection in mice by pretreatment with Lactobacillus brevis KB290 andverification using in vivo bioluminescence imaging, FEMS Microbiol Lett., 364, 6, 2017.
24) Yoshimatsu K, Koide H, Hoshino Y, Shea KJ, Preparation of abiotic polymer nanoparticles for sequestrationand neutralization of a target peptide toxin, Nature Protocols, 4, 595-604, 2015.
25) Koide H, Asai T, Kato H, Yonenaga N, Yokota M, Ando H, Dewa T, Nango M, Maeda N, Oku N, Susceptibilityof PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin,Nanomedicine, 1, 185-194, 2015.
26) Ando H, Asai T, Koide H, Okamoto A, Maeda N, Tomita K, Dewa T, Minamino T, Oku N., Advanced cancer
therapy by integrative antitumor actions via systemic administration of miR-499, J Control Release, 181,32-39, 2014.
27) Siripong P, Yahuafai J, Piyaviriyakul S, Kanokmedhakul K, Koide H, Ishii T, Shimizu K, Ruchirawat S, Oku N,
Inhibitory effect of liposomal rhinacanthin-N isolated from Rhinacanthus nasutus on pulmonary metastasis inmice, Biol Pharm Bull., 35, 1197-1200, 2012.
28) Koide H, Asai T, Kato H, Ando H, Shiraishi K, Yokoyama M, Oku N, Size-dependent induction of accelerated
blood clearance phenomenon by repeated injections of polymeric micelles, Int J Pharm., 432, 75-79, 2012.
29) Hoshino Y, Koide H, Furuya K, Haberaecker W W., Lee S, Kodama T, Kanawaza H, Oku N, and Shea K J,
The rational design of a plastic antidote: synthetic polymer nanoparticles that neutralize toxic peptides in vivo,Proc Natl Acad Sci USA, 109, 33-38, 2012.

30) Asai T, Matsushita S, Kenjo E, Tsuzuku T, Yonenaga N, Koide H, Hatanaka K, Dewa T, Nango M, Maeda N,Kikuchi H, and Oku N, Dicetylphosphate-tetra ethylenepentamine-based Liposomes for Systemic siRNADelivery, Bioconjug Chem., 22, 429-435. 2011.
31) Koide H Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N, and Oku N, Inhibition of Akt(ser473) phosphorylation and rapamycin-resistant cell growth by mammalian target of rapamycin knockdownwith siRNA in VEGFR-1 targeting vector, Biol. Pharm. Bull., 34, 602-608. 2011.
32) Asakawa T, Hiza A, Nakayama M, Inai M, Oyama D, Koide H, Shimizu K, Wakimoto T, Harada N, Tsukada H,Oku N and Kan T, PET imaging of nobiletin based on a practical total synthesis, Chem. Commun. (Camb).
47. 2868-2870. 2011.
33) Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H and Oku N, T
cell-independent B cell response is responsible for ABC phenomenon induced by repeatedinjection ofPEGylated liposomes, Int. J. Pharm., 392, 218-223. 2010.
34) Hoshino Y, Koide H, Urakami T, Kanazawa H, Kodama T, Oku N and Kenneth J. S, Recognition,neutralization, and clearance of target peptides in the bloodstream of living mice by molecularly imprinted
polymer nanoparticles: a plastic antibody, J. Am. Chem. Soc., 132, 6644-6645. 2010.
35) Hatanaka K, Asai T, Koide H, Kenjo E, Tsuzuku T, Harada N, Tsukada H and Oku N, Development ofdouble-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positronemission tomography, Bioconjug. Chem., 21, 756- 763, 2010.
36) Hoshino Y, Urakami T, Kodama T, Koide H, Oku N, Okahata Y and Shea KJ, Design of synthetic polymer
nanoparticles that capture and neutralize a toxic peptide, Small., 5, 1562-1568, 2009.
37) Urakami T, Kawaguchi A, Akai S, Hatanaka K, Koide H, Shimizu K, Asai T, Fukumoto D, Harada N, Tsukada
H and Oku N, In vivo trafficking of liposome-encapsulated hemoglobin determined by positron emission
tomography, Artificial Organs, 33, 164-168, 2009.
38) Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, Nishihara M, Yokoyama M, Ishida T, Kiwada H andOku N, Particle size-dependent triggering of accelerated blood clearance phenomenon, Int. J. Pharm., 362,197-200, 2008.
39) Imanaka H, Koide H, Shimizu K, Asai T, Shimizu K N, Ishikado A, Makino T and Oku N, Chemoprevention oftumor metastasis by liposomal beta-sitosterol intake, Biol. Pharm. Bull., 31, 400-404, 2008.
40) Hashimoto M, Takashige K, Furuyashiki M, Yoshidome K, Sano R, Kawamura Y, Ijichi S, Morioka H, Koide H,Oku N, Moriya Y, Kusumoto S and Suda Y., Enhancement of antitumor activity of OK-432 (Picibanil) by Triton
X-114 phase partitioning, Int. Immunopharmacology., 8, 12-19, 2008.

b) REVIEWS
1) Koide H, Design of synthetic polymer nanoparticles that capture and neutralize target molecules, Yakugaku
Zasshi, 141, 1079-1086. 2021.
2) Koide H, Yonezawa S, Asai T., siRNA Vehicles for High Endosomal Escapability. Methods Mol Biol. 2282,
171-179, 2021.

3) Koide H*., Design of Functional Nanoparticles for Intractable Disease Therapy. Biol Pharm Bull. 44, 1-6,2021.
4) Yonezawa S, Koide H, Asai T., Recent advances in siRNA delivery mediated by lipid-based nanoparticles.
Adv Drug Deliv Rev. 154, 64-78, 2020.
5) Koide H, Asai T, Shimizu K and Oku N, Drug carrier systems for anticancer agents, CRC press. Medicinaland Pharmaceutical Applications, Volume 2, 153–170, 2013.
6) Ando H, Yonenaga N, Asai T, Hatanaka K, Koide H, Tsuzuku T, Harada N, Tsukada H, Oku N, In vivo imagingof liposomal small interfering RNA (siRNA) trafficking by positron emission tomography, YAKUGAKUZASSHI, Review, 12, 1373-1381, 2012.
7) Koide H, Asai T, Hatanaka K, Shimizu K, Yokoyama M, Ishida T, Kiwada H, and Oku N, Elucidation ofaccelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers,YAKUGAKU ZASSHI, Review, 129, 1445-1451, 2009.